Julie Schloemer, MD
Dermatology · Findlay, OHNPI 1073933628
Payments from drug & device makers
Across 34 payments — averaging $23.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$155
- E.r. Squibb & Sons, L.L.C.$98
- Janssen Scientific Affairs, LLC$84
- Novartis$73
- AbbVie$70
- Lilly USA, LLC$57
- plus $250 from 10 others
What the payments were for
- Food & beverage$68987%
- Education$9913%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 4 | $155 |
| E.r. Squibb & Sons, L.L.C. | 4 | $98 |
| Janssen Scientific Affairs, LLC | 1 | $84 |
| Novartis | 5 | $73 |
| AbbVie | 4 | $70 |
| Lilly USA, LLC | 3 | $57 |
| Galderma Laboratories, L.p. | 3 | $41 |
| Sanofi | 1 | $39 |
| Arcutis Biotherapeutics, Inc. | 2 | $31 |
| UCB, Inc. | 1 | $29 |
| Incyte Corporation | 1 | $24 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Bristol Myers Squibb | 1 | $16 |
| Acera Surgical, Inc. | 1 | $16 |
| Pfizer | 1 | $14 |
How this compares
$788 in reported general payments places this provider in the 30th percentile of 460 dermatology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 70 | $341,446 |
| Humira(Cf) PenAdalimumab | 12 | $203,811 |
| Fluocinonide | 75 | $2,762 |
| Clobetasol Propionate | 59 | $2,061 |
| Fluorouracil | 23 | $2,019 |
| Ketoconazole | 92 | $1,637 |
| Betamethasone Dipropionate | 34 | $1,183 |
| Mycophenolate Mofetil | 22 | $1,158 |
| Triamcinolone Acetonide | 99 | $911 |
| Clindamycin Phosphate | 17 | $799 |
| Doxycycline Monohydrate | 32 | $659 |
| Metronidazole | 17 | $648 |
| Mometasone Furoate | 22 | $382 |
| Finasteride | 60 | $378 |
| Dutasteride | 21 | $369 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Findlay
- Matthew ZirwasBexley$7.4M
- Neil KormanCleveland$6M
- Jeffrey TraversDayton$4.7M
- Jennifer NashWesterville$4M
- Jessica KaffenbergerColumbus$3.2M
- Rocco SerraoDayton$3M
- Patrick ShannonBoardman$2M
- George DrewMarion$2M
- Benjamin BoguckiColumbus$2M
- Michelle ChambersColumbus$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.